GGrantIndex
← Leaderboards

Carolyn A Felix

Children'S Hospital Of Philadelphia

$7,871,940
Attributed
$7,871,940
Total exposure
5
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $598.4K · FY200514
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14

Funding mix

By agency

NIH$7,871,940 · 5

By mechanism

R01$7,871,940 · 4
M01$0 · 1

Top collaborators

No co-investigators on record.

Most similar at Children'S Hospital Of Philadelphia

Same institution · by research overlap

Others in their field

Top investigators on “Leukemia

Research focus

LeukemiaChromosome TranslocationNeoplasm /Cancer GeneticsClinical ResearchHuman SubjectPolymerase Chain ReactionPediatric Neoplasm /CancerDna GyraseEtoposideGene ExpressionEnzyme InhibitorsSouthern BlottingCytochrome P450Microarray TechnologyDrug Adverse EffectAntineoplasticsDna DamageMolecular CloningDrug CarcinogenesisPodophyllinApoptosisAlkylating AgentsAntineoplastic AgentsEnzyme Activity

Grant awards (26)

MLL in Hematopoiesis and Leukemia in the Zebrafish Model$384,562
R01 · FY2014 · CA · contact PI
MLL in Hematopoiesis and Leukemia in the Zebrafish Model$375,268
R01 · FY2013 · CA · contact PI
MLL in Hematopoiesis and Leukemia in the Zebrafish Model$402,071
R01 · FY2012 · CA · contact PI
MLL in Hematopoiesis and Leukemia in the Zebrafish Model$416,334
R01 · FY2011 · CA · contact PI
MLL in Hematopoiesis and Leukemia in the Zebrafish Model$446,593
R01 · FY2010 · CA · contact PI
ANTINEOPLASTIC v LEUKEMOGENIC EPIPODOPHYLLOTOXIN EFFECTS$266,610
R01 · FY2007 · CA · contact PI
Molecular Genetic Changes in Leukemia in Infants$319,031
R01 · FY2006 · CA · contact PI
ANTINEOPLASTIC v lEUKEMOGENIC EPIPODOPHYLLOTOXIN EFFECTS$274,573
R01 · FY2006 · CA · contact PI
Molecular Genetic Changes in Leukemia in Infants$317,191
R01 · FY2005 · CA
ANTINEOPLASTIC v lEUKEMOGENIC EPIPODOPHYLLOTOXIN EFFECTS$281,181
R01 · FY2005 · CA
BIOMARKERS OF TREATMENT RELATED LEUKEMIA$369,395
R01 · FY2004 · CA
Molecular Genetic Changes in Leukemia in Infants$307,953
R01 · FY2004 · CA
ANTINEOPLASTIC v LEUKEMOGENIC EPIPODOPHYLLOTOXIN EFFECTS$281,181
R01 · FY2004 · CA
Molecular Genetic Changes in Leukemia in Infants$371,634
R01 · FY2003 · CA
BIOMARKERS OF TREATMENT RELATED LEUKEMIA$369,395
R01 · FY2003 · CA
ANTINEOPLASTIC v LEUKEMOGENIC EPIPODOPHYLLOTOXIN EFFECTS$321,131
R01 · FY2003 · CA
Molecular Genetic Changes in Leukemia in Infants$384,200
R01 · FY2002 · CA
BIOMARKERS OF TREATMENT RELATED LEUKEMIA$369,395
R01 · FY2002 · CA
ANTINEOPLASTIC VS LEUKEMOGENIC EPIPODOPHYLLOTOXIN EFFECTS$0
M01 · FY2002 · RR
BIOMARKERS OF TREATMENT RELATED LEUKEMIA$369,395
R01 · FY2001 · CA
MOLECULAR GENETIC CHANGES IN LEUKEMIA IN INFANTS$233,202
R01 · FY2001 · CA
ANTINEOPLASTIC V LEUKEMOGENIC EPIPODOPHYLLOTOXIN EFFECTS$229,996
R01 · FY2001 · CA
BIOMARKERS OF TREATMENT RELATED LEUKEMIA$324,253
R01 · FY2000 · CA
ANTINEOPLASTIC V LEUKEMOGENIC EPIPODOPHYLLOTOXIN EFFECTS$230,984
R01 · FY2000 · CA
MOLECULAR GENETIC CHANGES IN LEUKEMIA IN INFANTS$226,412
R01 · FY2000 · CA
ANTINEOPLASTIC VS LEUKEMOGENIC EPIPODOPHYLLOTOXIN EFFECTS$0
M01 · FY2000 · RR